Greenridge Global Cuts EUDA Health (NASDAQ:EUDA) Price Target to $2.75

EUDA Health (NASDAQ:EUDAFree Report) had its price target reduced by Greenridge Global from $6.00 to $2.75 in a research note published on Monday,Benzinga reports. Greenridge Global currently has a buy rating on the stock. Greenridge Global also issued estimates for EUDA Health’s FY2025 earnings at ($0.01) EPS and FY2026 earnings at $0.08 EPS.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of EUDA Health in a research note on Friday, January 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $2.75.

Check Out Our Latest Research Report on EUDA

EUDA Health Stock Performance

Shares of NASDAQ:EUDA opened at $0.50 on Monday. The firm has a market cap of $18.98 million, a price-to-earnings ratio of -4.18 and a beta of -0.11. The business has a 50-day simple moving average of $1.33 and a two-hundred day simple moving average of $2.00. EUDA Health has a fifty-two week low of $0.46 and a fifty-two week high of $4.30.

Institutional Trading of EUDA Health

A hedge fund recently raised its stake in EUDA Health stock. Citadel Advisors LLC grew its holdings in EUDA Health Holdings Limited (NASDAQ:EUDAFree Report) by 57.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 44,631 shares of the company’s stock after acquiring an additional 16,321 shares during the period. Citadel Advisors LLC owned 0.12% of EUDA Health worth $78,000 as of its most recent SEC filing. Institutional investors and hedge funds own 4.35% of the company’s stock.

EUDA Health Company Profile

(Get Free Report)

EUDA Health, Inc (NASDAQ:EUDA) is a healthcare technology company focused on the development and commercialization of digital health solutions and energy-based medical devices for women’s intimate health. The company’s platform combines non-invasive treatment devices with software-driven patient monitoring and analytics to support pelvic floor function, address stress urinary incontinence and enhance vaginal tissue health.

EUDA Health’s core product offerings utilize low-intensity radiofrequency energy delivered through proprietary handpieces to promote tissue remodeling and muscle activation.

Read More

Receive News & Ratings for EUDA Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EUDA Health and related companies with MarketBeat.com's FREE daily email newsletter.